Shilpa Medicare saw a rise in its share price after the launch of its third anti-cancer medication in India. The pharmaceutical launched the Indian-Brand generic of ibrutinib named ‘IBRUSHIL’.
It is an anti-cancer drug used in the treatments of patients suffering from Mantle Cell Lymphomas (MCL), Chronic Lymphocytic Leukaemia (CLL), and other linked cancer.
As per company filing, the medicine is obtainable in 140 mg capsules in packs of 30 and 120 capsules. The drug is termed more effective and easier to use. Moreover, it attacks cancer cells without damaging normal cells, causing fewer side effects.
In addition, the cost of treatment is to ease down from Rs 4.36 lakh to Rs 34,920. This is owing to the launch of IBRUSHIL.
Earlier, the company stated in a press release that it has received CDSCO’s Permission for manufacturing and marketing of Lenvatinib. Therefore, producing capsules of 4mg and 10mg in India. Further, it mentioned being the first company to gain approval for the production of Lenvatinib Capsules.
“Lenvatinib capsules is a generic equivalent and bioequivalent of the reference product, Lenvima, used in the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer and for the first-line treatment of patients with unresectable hepatocellular carcinoma,” the company said in the release, dated May 23, 2020.
